611 tumors from 544 children and young adults showed about 15% of mutations in relapsed or metastatic pediatric cancers could be traced to treatment, with platinum drugs driving most therapy-linked DNA damage.
Platinum agents including cisplatin, carboplatin and oxaliplatin left distinct mutational signatures that could appear within three months of treatment, while temozolomide, 5-FU and thiopurines contributed far smaller shares.
Tumors with strong platinum-linked signatures often activated genes tied to platinum resistance, and patients carrying those patterns had worse outcomes on platinum therapy; the link was also seen in adults.
The Nature study suggests those signatures could be used as early warnings of drug-resistant clones, helping clinicians decide when to avoid reusing platinum drugs or lower doses in high-cure settings.
If chemotherapy fuels cancer's evolution, how can we design safer treatments for children?
Can real-time genomic tracking predict and prevent treatment-induced tumor relapse before it happens?
Therapy-Induced Mutational Signatures in Childhood Cancer: Breakthroughs in Relapse, Resistance, and Long-Term Care
Overview
A groundbreaking study published in Nature reveals that chemotherapy and other cancer treatments can leave distinct genetic 'scars' in childhood cancers that return after treatment. These therapy-induced mutations shape the genetic landscape of relapsed tumors, offering new insights into how cancer evolves and adapts after therapy. Understanding these specific mutation profiles is a major step forward, as it helps explain why some cancers become resistant and recur. This research marks a critical advancement in pediatric oncology, highlighting the complex relationship between cancer treatments and the long-term genetic changes they cause in young patients.